You are here

Article Text

Article menu
Download PDFPDF
Letters to JMG
Genetic testing in hereditary non-polyposis colorectal cancer families with a MSH2, MLH1, or MSH6 mutation
  1. A Wagner1,2,
  2. C Tops2,
  3. J T Wijnen2,
  4. K Zwinderman3,
  5. C van der Meer1,
  6. M Kets1,
  7. M F Niermeijer1,
  8. J G M Klijn4,
  9. A Tibben1,
  10. H F A Vasen5,
  11. H Meijers-Heijboer1
  1. 1Department of Clinical Genetics, Erasmus Medical Centre, Rotterdam, The Netherlands
  2. 2Department of Human and Clinical Genetics, Leiden University Medical Centre, Leiden, The Netherlands
  3. 3Department of Medical Statistics, Leiden University Medical Centre, Leiden, The Netherlands
  4. 4Department of Medical Oncology, Erasmus University Medical Centre, Rotterdam, The Netherlands
  5. 5Foundation for the Detection of Hereditary Tumours, Leiden University Medical Centre, Leiden, The Netherlands
  1. Correspondence to:
 Dr H Meijers-Heijboer, Department of Clinical Genetics, University Hospital Rotterdam, Westzeedijk 114, 3016 AH Rotterdam, The Netherlands;
 meijers{at}kgen.fgg.eur.nl

https://doi.org/10.1136/jmg.39.11.833

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    About 5% of colorectal cancers are associated with the autosomal dominantly inherited cancer susceptibility syndrome hereditary non-polyposis colorectal cancer (HNPCC).1,2 HNPCC is characterised by a high risk of developing colorectal cancer and endometrial cancer at a young age (cumulative lifetime risk 80-90% and 30-40%, respectively), and by an increased risk of developing various other tumour types, such as ovarian, uroepithelial, small intestine, biliary tract, stomach, brain, and skin cancers.2–5 Germline mutations in one of three mismatch repair genes (MSH2, MLH1, and MSH6) were found to be responsible for a majority of HNPCC families.6–9

    Knowledge of the causative mutation in a particular HNPCC family enables the identification of at risk family members by genetic testing. Clearly, the absence or presence of a mutation is of considerable medical and psychological significance. Subjects not carrying the mutation are relieved from a continuous anxiety and can be dismissed from medical surveillance, saving them trouble and reducing health care costs.10 Importantly, subjects with the mutation can benefit from a medical surveillance programme. For HNPCC, colonoscopy has been shown to be a potent tool for the detection and treatment of premalignant adenomas or early colorectal carcinomas in at risk subjects, reducing the risk of developing colorectal cancer and decreasing the overall mortality by about 65%.11,12 The possibility of early detection of colorectal cancer by stool analysis using the genetic markers TP53, BAT26, and K-RAS raises expectations for the development of less invasive surveillance procedures.13 Furthermore, intervention trials with non-steroidal anti-inflammatory drugs (NSAID) in subjects at risk for developing colorectal cancer are in progress.14,15

    So far, studies on the use of genetic testing in HNPCC families have used families or subjects who had been registered for research purposes.10,16,17 It is …

    View Full Text